AARDVARK THERAPEUTICS, INC. Stock-Based Compensation
AARDVARK THERAPEUTICS, INC. (AARD) reported Stock-Based Compensation of $3.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- AARDVARK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.95M, a 207.57% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.00M, a 760.09% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.58M, a 813.87% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.50M, a 934.48% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $3.95M, a 799.32% increase from fiscal 2024.
- AARDVARK THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $439.00K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.95M 10-Q · filed 2026-08-11 | $5.54M derived: sum of 3 quarters · filed 2026-08-11 | $7.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-07 | $3.58M derived: sum of 2 quarters · filed 2026-05-07 | $5.08M derived: sum of 3 quarters · filed 2026-05-07 | $5.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.08M derived: sum of 2 quarters · filed 2026-03-23 | $3.71M derived: sum of 3 quarters · filed 2026-08-11 | $3.95M 10-K · filed 2026-03-23 |
| 2025-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.13M derived: sum of 2 quarters · filed 2026-08-11 | $2.37M 10-Q · filed 2025-11-13 | $2.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $634.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $867.00K 10-Q · filed 2026-08-11 | $1.04M derived: sum of 3 quarters · filed 2026-08-11 | $1.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $233.00K 10-Q · filed 2026-05-07 | $406.00K derived: sum of 2 quarters · filed 2026-05-07 | $551.00K derived: sum of 3 quarters · filed 2026-05-07 | $605.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $173.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $318.00K derived: sum of 2 quarters · filed 2026-03-23 | $372.00K derived: sum of 3 quarters · filed 2026-03-23 | $439.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $145.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $199.00K derived: sum of 2 quarters · filed 2025-11-13 | $266.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $121.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $67.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |